Priovant nabs first FDA approval for targeted tablet in dermatomyositis

Priovant receives first FDA approval for targeted tablet in dermatomyositis

Priovant Therapeutics secured its first FDA approval for a targeted tablet treatment for dermatomyositis, a rare autoimmune disease affecting muscles and skin.